© 2019 AAVANTI Biotherapeutics & AAVANTI, LLC

Investors & Partners

AavantiBio is a U.S.-based early stage biotech company focused on the development of gene therapy for Friedreich's Ataxia.  The company is working on the first treatment that targets the source of the disease.

Want to join the AavantiBio team at the cutting edge of gene therapy research?

Feel free to reach out! We'd be happy to chat.